FDA could gain new powers next year

11/3/2006 | RPM Report (free registration), The

The FDA could gain several new powers when Congress examines drug safety reforms next year, including greater authority over prescription labels. Other changes could include requiring risk management plans for new drugs, establishing post-market PDUFA goals for safety issues, and clinical trial registration for Phase II, III and IV studies.

View Full Article in:

RPM Report (free registration), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA